Demographic and clinical disease activity characteristics of patients with PsA in LDA.
| Characteristics | Values |
|---|---|
| Female/male, n | 49/64 |
| Mean age (SD), yrs | 53.7 (12.4) |
| Disease duration, mean (SD), yrs | 8 (8.8) |
| Axial involvement, n (%) | 42 (37.1) |
| Tender joints, median (IQR) | 1 (0–2) |
| Swollen joints, median (IQR) | 0 (0–1) |
| BSA, % (IQR) | 1 (1–3) |
| PASI, median (IQR) | 0.3 (0–1) |
| Enthesitis (LEI), median (IQR) | 0 (0–0) |
| CRP, mg/dl, median (IQR) | 0.3 (0.2–0.4) |
| MDA 5/7, n (%) | 78 (69) |
| VLDA, n (%) | 32 (28.3) |
| DAPSA remission | 46 (40.7) |
| HAQ, median (IQR) | 0.25 (0.125–0.5) |
| VAS pain, median (IQR) | 16.5 (10–30) |
| PtGA, median (IQR) | 20 (10–30) |
| VAS physician, median (IQR) | 15 (10–23.5) |
| Treatment, n (%) | |
| csDMARD monotherapy | 22 (19.4) |
| Etanercept | 32 (28.3) |
| Adalimumab | 23 (20.3) |
| Golimumab | 13 (11.5) |
| Ustekinumab | 5 (4.4) |
| Secukinumab | 16 (14.1) |
| Ixekizumab | 2 (1.7) |
PsA: psoriatic arthritis; LDA: low disease activity; IQR: interquartile range; BSA: body surace area; LEI: Leeds Enthesitis Index; PASI: Psoriasis Area Severity Index; CRP: C-reactive protein; MDA: minimal disease activity; VLDA: very low disease activity; DAPSA: Disease Activity Index for Psoriatic Arthritis; HAQ: Health Assessment Questionnaire; VAS: visual analog scale; PtGA: patient’s global assessment; csDMARD: conventional synthetic disease-modifying antirheumatic drugs.